0001594062-17-000047.txt : 20170228 0001594062-17-000047.hdr.sgml : 20170228 20170228172906 ACCESSION NUMBER: 0001594062-17-000047 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20170224 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20170228 DATE AS OF CHANGE: 20170228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cell MedX Corp. CENTRAL INDEX KEY: 0001493712 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-MISCELLANEOUS RETAIL [5900] IRS NUMBER: 383939625 STATE OF INCORPORATION: NV FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54500 FILM NUMBER: 17649540 BUSINESS ADDRESS: STREET 1: 123 W. NYE LN, SUITE 446 CITY: CARSON CITY STATE: NV ZIP: 89706 BUSINESS PHONE: (844) 238-2692 MAIL ADDRESS: STREET 1: 123 W. NYE LN, SUITE 446 CITY: CARSON CITY STATE: NV ZIP: 89706 FORMER COMPANY: FORMER CONFORMED NAME: Sports Asylum, Inc. DATE OF NAME CHANGE: 20140324 FORMER COMPANY: FORMER CONFORMED NAME: Plandel Resources, Inc. DATE OF NAME CHANGE: 20100608 8-K 1 form8k.htm 8-K form8k.htm



 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):    February 24, 2017


CELL MEDX CORP.
(Exact name of registrant as specified in its charter)


NEVADA
000-54500
38-3939625
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
     
123 W. Nye Ln, Suite 446
Carson City, NV
 
89706
(Address of principal executive offices)
 
(Zip Code)
     
 
Registrant's telephone number, including area code:
  (844) 238-2692

n/a
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[   ]           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[   ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[   ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[   ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
1

 


ITEM 7.01
REGULATION FD DISCLOSURE

On February 24, 2017, Cell MedX Corp. (the “Company”) issued an informational news release (the “Release”) announcing the engagement of Think Ink Marketing Data & Email Services, Inc. (“Think Ink”) to develop an investor outreach program for the Company. A copy of the Release is attached to this Current Report on Form 8-K as Exhibit 99.1.

The information furnished pursuant to Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

ITEM 9.01             FINANCIAL STATEMENTS AND EXHIBITS.

(d)           Exhibits

The following exhibits are either provided with this Current Report or are incorporated herein by reference:

Exhibit Number
Description of Exhibit
99.1
News Release dated February 24, 2017.


 

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
CELL MEDX CORP.
Date:  February 28, 2017
By:           /s/ Frank McEnulty
Frank McEnulty,
Chief Executive Officer

 
2

 

EX-99.1 2 ex991.htm NEWS RELEASE DATED FEBRUARY 24, 2017 ex991.htm




CELL MEDX CORP. OTCQB: CMXC
FOR IMMEDIATE RELEASE FEBRUARY 24th, 2017

Cell MedX Corp. Engages Think Ink Marketing

Carson City, Nevada, February 24, 2017, Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. (“Cell MedX” or the “Company”), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that, it has retained Think Ink Marketing Data & Email Services, Inc. (“Think Ink”) to develop an investor outreach program. The Company agreed to pay Think Ink a one-time fee of $75,000 for the first month of their services.

Think Ink Marketing Data & Email Services, Inc. is a California-based marketing firm established in 2013 that provides its customers with a complete range of marketing services that span both digital and direct mail venues. With its digital services ranging from data appending, email marketing and pay-per-click online banner and native ads, the company helps its clients to reach a large network of potential investors.

About Cell MedX Corp.

Cell MedX Corp. is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, high blood pressure. For more information about the Company and its technology please visit our website at: www.cellmedx.com, for the Company's newsletter, please go to www.cellmedx.com/media/newsletters/

On behalf of the Board of Directors of Cell MedX Corp.

Frank McEnulty
Chief Executive Officer and President.
 
Forward Looking Statements
The information included in this press release has not been reviewed by the FDA, nor has it been peer reviewed. This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company’s eBalance technology is still in development.  Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.

SOURCE:
Cell MedX Corp.
For further information visit: www.cellmedx.com. 
Or phone: 1-844-238-2692




 
 

 

GRAPHIC 3 cellmedxlogo1.jpg LOGO begin 644 cellmedxlogo1.jpg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end